A potential new biomarker — Index of cardiac electrophysiological balance (iCEB) — For detecting drug-induced cardiac arrhythmias in isolated rabbit Langendorff hearts

2014 ◽  
Vol 70 (3) ◽  
pp. 330
Author(s):  
An N. Hermans ◽  
Danny Geyskens ◽  
Hua Rong Lu ◽  
David J. Gallacher
Author(s):  
Lindsay N. Moreland-Head ◽  
James C. Coons ◽  
Amy L. Seybert ◽  
Matthew P. Gray ◽  
Sandra L. Kane-Gill

Introduction: Drug-induced QTc-prolongation is a well-known adverse drug reaction (ADR), however there is limited knowledge of other drug-induced arrhythmias. Purpose: The objective of this study is to determine the drugs reported to be associated with arrhythmias other than QTc-prolongation using the FAERS database, possibly identifying potential drug causes that have not been reported previously. Methods: FAERS reports from 2004 quarter 1 through 2019 quarter 1 were combined to create a dataset of approximately 11.6 million reports. Search terms for arrhythmias of interest were selected from the Standardized MedDRA Queries (SMQ) Version 12.0. Frequency of the cardiac arrhythmias were determined for atrial fibrillation, atrioventricular block, bradyarrhythmia, bundle branch block, supraventricular tachycardia, and ventricular fibrillation and linked to the reported causal medications. Reports were further categorized by prior evidence associations using package inserts and established drug databases. A reporting odds ratio (ROR) and confidence interval (CI) were calculated for the ADRs for each drug and each of the 6 cardiac arrhythmias. Results: Of the 11.6 million reports in the FAERS database, 68,989 were specific to cardiac arrhythmias of interest. There were 61 identified medication-reported arrhythmia pairs for the 6 arrhythmia groups with 33 found to have an unknown reported association. Rosiglitazone was the most frequently medication reported across all arrhythmias [ROR 6.02 (CI: 5.82-6.22)]. Other medications with significant findings included: rofecoxib, digoxin, alendronate, lenalidomide, dronedarone, zoledronic acid, adalimumab, dabigatran, and interferon beta-1b. Conclusion: Upon retrospective analysis of the FAERS database, the majority of drug-associated arrhythmias reported were unknown suggesting new potential drug causes. Cardiac arrhythmias other than QTc prolongation are a new area of focus for pharmacovigilance and medication safety. Consideration of future studies should be given to using the FAERS database as a timely pharmacovigilance tool to identify unknown adverse events of medications.


Iatrogenicity ◽  
2018 ◽  
pp. 62-76
Author(s):  
Aalap Narichania ◽  
Yasuhiro Yokoyama ◽  
Win K. Shen

2017 ◽  
Vol 280 ◽  
pp. S24
Author(s):  
Hua Rong Lu ◽  
Ivan Kopljar ◽  
Kreir Mohamed ◽  
Ard Teisman ◽  
David J. Gallacher

Diseases ◽  
2019 ◽  
Vol 7 (2) ◽  
pp. 38 ◽  
Author(s):  
Prashanth Rawla ◽  
Jeffrey Pradeep Raj ◽  
Sajid Melvin George ◽  
Pavani Nathala ◽  
Anantha R. Vellipuram

Rhabdomyolysis is caused by extensive damage to skeletal muscles resulting in elevated creatine phosphokinase (CPK), Lactate dehydrogenase (LDH), and aspartate aminotransferase (AST), leading to life-threatening consequences like acute renal failure, cardiac arrhythmias, and hyperthermia. A variety of causes for muscle damage are known, and one of the most common is drug-induced. Statins and many other agents are known to induce muscle damage, but here we report Entresto™ (Sacubitril/Valsartan) induced rhabdomyolysis which has not been previously reported as solely responsible in the literature.


2017 ◽  
Vol 240 ◽  
pp. 354-359 ◽  
Author(s):  
Marco Antonio Vidal Jiménez ◽  
José H.M. Nascimento ◽  
Gustavo Monnerat ◽  
Leonardo Maciel ◽  
Claudia N. Paiva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document